Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
This study is testing a new vaccine that aims to protect babies from serious illnesses like meningitis. The main goals are to see if it's safe, how well babies tolerate it, and if it helps their bodies build protection against these infections.
For: Infections · MeningococcalPoland · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Proof of concept study to assess the efficacy and safety of Danicopan (factor D inhibitor) in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment (DANICSU).
This study looks at a new medicine called Danicopan for adults with long-lasting hives (urticaria) that haven't gotten better with standard allergy pills. It aims to see if Danicopan is safe and helps reduce hives, especially for those with different allergy levels.
For: Chronic spontaneous urticariaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, open-label, multi-center study to assess the immune response and safety of the meningococcal group B vaccine rMenB+OMV NZ when administered to healthy participants aged 10 to 20 years old, who were primed during the first 2 years of life
This study is looking at how well a meningitis B vaccine, Bexsero, works and how safe it is in young people aged 10-20. Participants would have had their first meningitis B vaccinations as babies. We want to see if a booster dose helps protect them.
For: Invasive meningococcal disease (IMD)Italy · Finland · Spain - AuthorisedPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
This study is testing a new medicine, IM-101, for adults with Myasthenia Gravis (MG). It's looking at how safe it is and how well it works to improve symptoms of generalized and ocular MG.
For: Generalized Myasthenia Gravis and Ocular Myasthenia GravisBulgaria · Poland · Spain